Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 vaccine in patients with CLL. We evaluated humoral immune responses to the BNT162b2 messenger RNA (mRNA) COVID-19 vaccin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Herishanu, Yair, Avivi, Irit, Aharon, Anat, Shefer, Gabi, Levi, Shai, Bronstein, Yotam, Morales, Miguel, Ziv, Tomer, Shorer Arbel, Yamit, Scarfò, Lydia, Joffe, Erel, Perry, Chava, Ghia, Paolo
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2021
Soggetti:
CLINICAL TRIALS AND OBSERVATIONS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8061088/
https://ncbi.nlm.nih.gov/pubmed/33861303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2021011568
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi